Company intelligence / Profile preview

Otida

Ownership: Private
Development stage: Commercial

Overview

Otida offers an AI-driven digital health platform for comprehensive chronic disease management. The system integrates wearable devices for continuous glucose monitoring and other health metrics, provides personalized coaching and recommendations, supports remote patient monitoring by healthcare teams, and has demonstrated significant improvements in glycemic control and weight loss among users. Patient outcomes include substantial reductions in HbA1c levels and medication dosages as well as weight loss.

Therapeutic areas: EndocrinologyCardiovascularNephrology
Modalities: Digital therapeuticsWearable device integrationRemote monitoringAI-powered decision support system
Industry: Digital Health Medical Devices

Partnerships

Works with pharmaceutical companies to develop patient support programs for insulin therapy and GLP‑1 agonists; no specific pharma partners named publicly.

Beyond the preview

Go deeper on Otida.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otida.

Explore the full profile